A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice

Vaccine

Volumn 27, Issue 22, 2009, Pages 2967-2980

  Wang, Jie ^a,c   Chen, Lili ^a   Chen, Fan ^a,c   Zhang, Xiaoyun ^a   Zhang, Yingqian ^a   Baseman, Joel ^a   Perdue, Sondra ^a   Yeh, I Tien ^a   Shain, Rochelle ^a   Holland, Martin ^b   Bailey, Robin ^b   Mabey, David ^b   Yu, Ping ^c   Zhong, Guangming ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Central South University   (China)

Author keywords

Chlamydia trachomatis type III secretion; Human antibodies; Inflammatory pathologies; Mouse urogenital tract infection; Tarp; Vaccine

Indexed keywords

ANTISERUM; BACTERIAL PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; FREUND ADJUVANT; TYPE III SECRETED EFFECTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; GENITAL TRACT INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TYPE III SECRETION SYSTEM;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; FALLOPIAN TUBES; FEMALE; HELA CELLS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; VIRULENCE FACTORS;

EID: 65049091364     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.095     Document Type: Article

References (86)

1. Taylor H.R., Johnson S.L., Schachter J., Caldwell H.D., and Prendergast R.A. Pathogenesis of trachoma: the stimulus for inflammation. J Immunol 138 9 (1987) 3023-3027
2. Sherman K.J., Daling J.R., Stergachis A., Weiss N.S., Foy H.M., Wang S.P., et al. Sexually transmitted diseases and tubal pregnancy. Sex Transm Dis 17 3 (1990) 115-121
3. Kinnunen A.H., Surcel H.M., Lehtinen M., Karhukorpi J., Tiitinen A., Halttunen M., et al. HLA DQ alleles and interleukin-10 polymorphism associated with Chlamydia trachomatis-related tubal factor infertility: a case-control study. Hum Reprod 17 8 (2002) 2073-2078
4. Bauwens J.E., Orlander H., Gomez M.P., Lampe M., Morse S., Stamm W.E., et al. Epidemic lymphogranuloma venereum during epidemics of crack cocaine use and HIV infection in the Bahamas. Sex Transm Dis 29 5 (2002) 253-259
5. Schachter J., and Moncada J. Lymphogranuloma venereum: how to turn an endemic disease into an outbreak of a new disease? Start looking. Sex Transm Dis 32 6 (2005) 331-332
6. Spaargaren J. Slow epidemic of lymphogranuloma venereum l2b strain. Emerg Infect Dis 11 11 (2005) 1787-1788
7. Cotter T.W., Meng Q., Shen Z.L., Zhang Y.X., Su H., and Caldwell H.D. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun 63 12 (1995) 4704-4714
8. Perry L.L., Feilzer K., Hughes S., and Caldwell H.D. Clearance of Chlamydia trachomatis from the murine genital mucosa does not require perforin-mediated cytolysis or Fas-mediated apoptosis. Infect Immun 67 3 (1999) 1379-1385
9. Pal S., Peterson E.M., and de la Maza L.M. Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun 73 12 (2005) 8153-8160
10. Barteneva N., Theodor I., Peterson E.M., and de la Maza L.M. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infect Immun 64 11 (1996) 4830-4833
11. Zhang D., Yang X., Lu H., Zhong G., and Brunham R.C. Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation. Infect Immun 67 4 (1999) 1606-1613
12. Lu H., and Zhong G. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect Immun 67 4 (1999) 1763-1769
13. Murthy A.K., Sharma J., Coalson J.J., Zhong G., and Arulanandam B.P. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol 230 1 (2004) 56-64
14. Cheng W., Shivshankar P., Li Z., Chen L., Yeh I.T., and Zhong G. Caspase-1 contributes to Chlamydia trachomatis-induced upper urogenital tract inflammatory pathologies without affecting the course of infection. Infect Immun 76 2 (2008) 515-522
15. Shah A.A., Schripsema J.H., Imtiaz M.T., Sigar I.M., Kasimos J., Matos P.G., et al. Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex Transm Dis 32 1 (2005) 49-56
16. Patton D.L., Landers D.V., and Schachter J. Experimental Chlamydia trachomatis salpingitis in mice: initial studies on the characterization of the leukocyte response to chlamydial infection. J Infect Dis 159 6 (1989) 1105-1110
17. Morrison R.P., and Caldwell H.D. Immunity to murine chlamydial genital infection. Infect Immun 70 6 (2002) 2741-2751
18. Morrison S.G., and Morrison R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol 175 11 (2005) 7536-7542
19. Fling S.P., Sutherland R.A., Steele L.N., Hess B., D'Orazio S.E., Maisonneuve J., et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. Proc Natl Acad Sci USA 98 3 (2001) 1160-1165
20. Lampe M.F., Wilson C.B., Bevan M.J., and Starnbach M.N. Gamma interferon production by cytotoxic T lymphocytes is required for resolution of Chlamydia trachomatis infection. Infect Immun 66 11 (1998) 5457-5461
21. Read T.D., Brunham R.C., Shen C., Gill S.R., Heidelberg J.F., White O., et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res 28 6 (2000) 1397-1406
22. Read T.D., Myers G.S., Brunham R.C., Nelson W.C., Paulsen I.T., Heidelberg J., et al. Genome sequence of Chlamydophila caviae (Chlamydia psittaci GPIC): examining the role of niche-specific genes in the evolution of the Chlamydiaceae. Nucleic Acids Res 31 8 (2003) 2134-2147
23. Stephens R.S., Kalman S., Lammel C., Fan J., Marathe R., Aravind L., et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282 5389 (1998) 754-759
24. Hackstadt T. The diverse habitats of obligate intracellular parasites. Curr Opin Microbiol 1 1 (1998) 82-87
25. Hackstadt T., Fischer E.R., Scidmore M.A., Rockey D.D., and Heinzen R.A. Origins and functions of the chlamydial inclusion. Trends Microbiol 5 7 (1997) 288-293
26. Stuber K., Frey J., Burnens A.P., and Kuhnert P. Detection of type III secretion genes as a general indicator of bacterial virulence. Mol Cell Probes 17 1 (2003) 25-32
27. Hueck C.J. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 62 2 (1998) 379-433
28. Galan J.E., and Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 284 5418 (1999) 1322-1328
29. Bannantine J.P., Griffiths R.S., Viratyosin W., Brown W.J., and Rockey D.D. A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane. Cell Microbiol 2 1 (2000) 35-47
30. Toh H., Miura K., Shirai M., and Hattori M. In silico inference of inclusion membrane protein family in obligate intracellular parasites chlamydiae. DNA Res 10 1 (2003) 9-17
31. Peters J., Wilson D.P., Myers G., Timms P., and Bavoil P.M. Type III secretion a la Chlamydia. Trends Microbiol 15 6 (2007) 241-251
32. Hefty P.S., and Stephens R.S. Chlamydial type III secretion system is encoded on ten operons preceded by sigma 70-like promoter elements. J Bacteriol 189 1 (2007) 198-206
33. Rockey D.D., Heinzen R.A., and Hackstadt T. Cloning and characterization of a Chlamydia psittaci gene coding for a protein localized in the inclusion membrane of infected cells. Mol Microbiol 15 4 (1995) 617-626
34. Rockey D.D., Scidmore M.A., Bannantine J.P., and Brown W.J. Proteins in the chlamydial inclusion membrane. Microbes Infect 4 3 (2002) 333-340
35. Li Z., Chen C., Chen D., Wu Y., Zhong Y., and Zhong G. Characterization of fifty putative inclusion membrane proteins encoded in the Chlamydia trachomatis genome. Infect Immun 76 6 (2008) 2746-2757
36. Valdivia R.H. Chlamydia effector proteins and new insights into chlamydial cellular microbiology. Curr Opin Microbiol 11 1 (2008) 53-59
37. Li Z., Chen D., Zhong Y., Wang S., and Zhong G. The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun 76 8 (2008) 3415-3428
38. Zhong G., Fan P., Ji H., Dong F., and Huang Y. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. J Exp Med 193 8 (2001) 935-942
39. Subtil A., Parsot C., and Dautry-Varsat A. Secretion of predicted Inc proteins of Chlamydia pneumoniae by a heterologous type III machinery. Mol Microbiol 39 3 (2001) 792-800
40. Subtil A., Delevoye C., Balana M.E., Tastevin L., Perrinet S., and Dautry-Varsat A. A directed screen for chlamydial proteins secreted by a type III mechanism identifies a translocated protein and numerous other new candidates. Mol Microbiol 56 6 (2005) 1636-1647
41. Fields K.A., and Hackstadt T. Evidence for the secretion of Chlamydia trachomatis CopN by a type III secretion mechanism. Mol Microbiol 38 5 (2000) 1048-1060
42. Ho T.D., and Starnbach M.N. The Salmonella enterica serovar typhimurium-encoded type III secretion systems can translocate Chlamydia trachomatis proteins into the cytosol of host cells. Infect Immun 73 2 (2005) 905-911
43. Muschiol S., Bailey L., Gylfe A., Sundin C., Hultenby K., Bergstrom S., et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA 103 39 (2006) 14566-14571
44. Wolf K., Betts H.J., Chellas-Gery B., Hower S., Linton C.N., and Fields K.A. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 61 6 (2006) 1543-1555
45. Betts H.J., Twiggs L.E., Sal M.S., Wyrick P.B., and Fields K.A. Bioinformatic and biochemical evidence for the identification of the type III secretion system needle protein of Chlamydia trachomatis. J Bacteriol 190 5 (2008) 1680-1690
46. Fields K.A., Fischer E.R., Mead D.J., and Hackstadt T. Analysis of putative Chlamydia trachomatis chaperones Scc2 and Scc3 and their use in the identification of type III secretion substrates. J Bacteriol 187 18 (2005) 6466-6478
47. Slepenkin A., de la Maza L.M., and Peterson E.M. Interaction between components of the type III secretion system of Chlamydiaceae. J Bacteriol 187 2 (2005) 473-479
48. Chellas-Gery B., Linton C.N., and Fields K.A. Human GCIP interacts with CT847, a novel Chlamydia trachomatis type III secretion substrate, and is degraded in a tissue-culture infection model. Cell Microbiol 9 10 (2007) 2417-2430
49. Zhong G., Fan T., and Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 189 12 (1999) 1931-1938
50. Zhong G., Liu L., Fan T., Fan P., and Ji H. Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 191 9 (2000) 1525-1534
51. Clifton D.R., Fields K.A., Grieshaber S.S., Dooley C.A., Fischer E.R., Mead D.J., et al. A chlamydial type III translocated protein is tyrosine-phosphorylated at the site of entry and associated with recruitment of actin. Proc Natl Acad Sci USA 101 27 (2004) 10166-10171
52. Backert S., and Selbach M. Tyrosine-phosphorylated bacterial effector proteins: the enemies within. Trends Microbiol 13 10 (2005) 476-484
53. Clifton D.R., Dooley C.A., Grieshaber S.S., Carabeo R.A., Fields K.A., and Hackstadt T. Tyrosine phosphorylation of the chlamydial effector protein Tarp is species specific and not required for recruitment of actin. Infect Immun 73 7 (2005) 3860-3868
54. Engel J. Tarp and Arp: how Chlamydia induces its own entry. Proc Natl Acad Sci USA 101 27 (2004) 9947-9948
55. Jewett T.J., Fischer E.R., Mead D.J., and Hackstadt T. Chlamydial TARP is a bacterial nucleator of actin. Proc Natl Acad Sci USA 103 42 (2006) 15599-15604
56. Jewett T.J., Dooley C.A., Mead D.J., and Hackstadt T. Chlamydia trachomatis tarp is phosphorylated by src family tyrosine kinases. Biochem Biophys Res Commun 371 2 (2008) 339-344
57. Lane B.J., Mutchler C., Al Khodor S., Grieshaber S.S., and Carabeo R.A. Chlamydial entry involves TARP binding of guanine nucleotide exchange factors. PLoS Pathog 4 3 (2008) e1000014
58. Greene W., Xiao Y., Huang Y., McClarty G., and Zhong G. Chlamydia-infected cells continue to undergo mitosis and resist induction of apoptosis. Infect Immun 72 1 (2004) 451-460
59. Zhong G., Toth I., Reid R., and Brunham R.C. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. J Immunol 151 7 (1993) 3728-3736
60. Zhong G., Reis e Sousa C., and Germain R.N. Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc Natl Acad Sci USA 94 25 (1997) 13856-13861
61. Zhong G., Berry J., and Brunham R.C. Antibody recognition of a neutralization epitope on the major outer membrane protein of Chlamydia trachomatis. Infect Immun 62 5 (1994) 1576-1583
62. Zhong G., and Brunham R.C. Antibody responses to the chlamydial heat shock proteins hsp60 and hsp70 are H-2 linked. Infect Immun 60 8 (1992) 3143-3149
63. Zhong G.M., and Brunham R.C. Antigenic determinants of the chlamydial major outer membrane protein resolved at a single amino acid level. Infect Immun 59 3 (1991) 1141-1147
64. Murthy A.K., Cong Y., Murphey C., Guentzel M.N., Forsthuber T.G., Zhong G., et al. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun 74 12 (2006) 6722-6729
65. Zhong G.M., and Brunham R.C. Immunoaccessible peptide sequences of the major outer membrane protein from Chlamydia trachomatis serovar C. Infect Immun 58 10 (1990) 3438-3441
66. Sharma J., Bosnic A.M., Piper J.M., and Zhong G. Human antibody responses to a Chlamydia-secreted protease factor. Infect Immun 72 12 (2004) 7164-7171
67. Cheng W., Shivshankar P., Zhong Y., Chen D., Li Z., and Zhong G. Intracellular interleukin-1alpha mediates interleukin-8 production induced by Chlamydia trachomatis infection via a mechanism independent of type I interleukin-1 receptor. Infect Immun 76 3 (2008) 942-951
68. Xiao Y., Zhong Y., Su H., Zhou Z., Chiao P., Zhong G., and NF-kappa. B activation is not required for Chlamydia trachomatis inhibition of host epithelial cell apoptosis. J Immunol 174 3 (2005) 1701-1708
69. Fan T., Lu H., Hu H., Shi L., McClarty G.A., Nance D.M., et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 187 4 (1998) 487-496
70. Zhong G., Castellino F., Romagnoli P., and Germain R.N. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J Exp Med 184 5 (1996) 2061-2066
71. Sharma J., Dong F., Pirbhai M., and Zhong G. Inhibition of proteolytic activity of a chlamydial proteasome/protease-like activity factor by antibodies from humans infected with Chlamydia trachomatis. Infect Immun 73 7 (2005) 4414-4419
72. Dong F., Zhong Y., Arulanandam B., and Zhong G. Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun 73 3 (2005) 1868-1872
73. Dong F., Pirbhai M., Xiao Y., Zhong Y., Wu Y., and Zhong G. Degradation of the proapoptotic proteins Bik, Puma, and Bim with Bcl-2 domain 3 homology in Chlamydia trachomatis-infected cells. Infect Immun 73 3 (2005) 1861-1864
74. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186 10 (1997) 1623-1631
75. Imtiaz M.T., Schripsema J.H., Sigar I.M., Kasimos J.N., and Ramsey K.H. Inhibition of matrix metalloproteinases protects mice from ascending infection and chronic disease manifestations resulting from urogenital Chlamydia muridarum infection. Infect Immun 74 10 (2006) 5513-5521
76. Murthy A.K., Chambers J.P., Meier P.A., Zhong G., and Arulanandam B.P. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun 75 2 (2007) 666-676
77. Sharma J., Zhong Y., Dong F., Piper J.M., Wang G., and Zhong G. Profiling of human antibody responses to Chlamydia trachomatis urogenital tract infection using microplates arrayed with 156 chlamydial fusion proteins. Infect Immun 74 3 (2006) 1490-1499
78. Yuan Y., Zhang Y.X., Watkins N.G., and Caldwell H.D. Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars. Infect Immun 57 4 (1989) 1040-1049
79. Carlson J.H., Porcella S.F., McClarty G., and Caldwell H.D. Comparative genomic analysis of Chlamydia trachomatis oculotropic and genitotropic strains. Infect Immun 73 10 (2005) 6407-6418
80. Fields K.A., Mead D.J., Dooley C.A., and Hackstadt T. Chlamydia trachomatis type III secretion: evidence for a functional apparatus during early-cycle development. Mol Microbiol 48 3 (2003) 671-683
81. Belland R.J., Zhong G., Crane D.D., Hogan D., Sturdevant D., Sharma J., et al. Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA 100 14 (2003) 8478-8483
82. Shaw E.I., Dooley C.A., Fischer E.R., Scidmore M.A., Fields K.A., and Hackstadt T. Three temporal classes of gene expression during the Chlamydia trachomatis developmental cycle. Mol Microbiol 37 4 (2000) 913-925
83. Morrison R.P., Feilzer K., and Tumas D.B. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 63 12 (1995) 4661-4668
84. Murphey C., Murthy A.K., Meier P.A., Neal Guentzel M., Zhong G., and Arulanandam B.P. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol 242 2 (2006) 110-117
85. Saikh K.U., Kissner T.L., Dyas B., Tropea J.E., Waugh D.S., and Ulrich R.G. Human cytolytic T cell recognition of Yersinia pestis virulence proteins that target innate immune responses. J Infect Dis 194 12 (2006) 1753-1760
86. Abe A., Nagamatsu K., and Watanabe M. The Bordetella type III secretion system: its application to vaccine development. Microbiol Immunol 52 2 (2008) 128-133